Shares of Quoin Pharmaceuticals (NASDAQ: QNRX) popped in morning trading on Tuesday after the specialty pharmaceutical company announced it will be initiating a second multicenter, open-label clinical trial in Netherton Syndrome patients. Netherton Syndrome is a skin disorder that affects the hair, skin, and immune system.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
This study will be conducted under the company’s currently open U.S. Investigational New Drug (IND) Application. This clinical trial will evaluate QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief.
Quoin CEO, Dr. Michael Myers, stated, “We are very pleased to announce our plan to initiate this second clinical study in Netherton patients under our open IND application. While there are no currently approved therapeutic treatments for Netherton Syndrome, we are aware that a subset of patients is being treated off-label with systemic biologics, including systemic therapy, that provide some symptomatic relief but do not address all symptoms, nor the underlying cause of the disease.”
